The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of galantamine in Alzheimer's disease at 3 months using flexible dose escalation. METHODS: A randomised, double blind, placebo controlled trial in 43 centres in the United States, Canada, Great Britain, South Africa, Australia, and New Zealand. Patients with probable Alzheimer's disease (n=386; 171 women) with a score of 11-24 on the mini mental state examination, and a score> or =12 on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog) were randomised to placebo, or galantamine escalated over 4 weeks to a maintenance dose of 24 or 32 mg/day. The primary outcome measures were the change in ADAS-cog score and the clinician's interview based impression of change plus caregiver input (CIBIC-plus) score. Activities of daily living (ADL) and behavioural symptoms were secondary outcomes. To compare the effects of highest levels of dosing, an observed cases (OC) analysis was undertaken, with classic intention to treat (ITT) and ITT with last observation carried forward (LOCF) as confirmatory analyses. RESULTS: At 3 months, galantamine (24-32 mg/day) produced a significantly better outcome on cognitive function than placebo (treatment difference=1.9 points on ADAS-cog, p=0.002) and a significantly better global response than placebo, as measured by CIBIC-plus (deterioration in 21% of patients on galantamine v 37% on placebo; p<0.001). Galantamine produced significant benefits on basic and instrumental ADL. Behavioural symptoms did not change significantly from baseline levels in either group. Adverse events (primarily gastrointestinal) were of mild to moderate intensity. There were no important differences between the OC, ITT, and ITT/LOCF analyses. Most patients (82%) who were maintained on the higher dose of galantamine completed the study. CONCLUSIONS: Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living. Flexible dose escalation of galantamine was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 1,495
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Rogers, S. L., & Friedhoff, L. T. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106895 · Cited by 742
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Nicotinic acetylcholine involvement in cognitive function in animals
Levin, E. D., & Simon, B. B. (1998) · Psychopharmacology · doi:10.1007/s002130050667 · Cited by 678
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 626
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.-J., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 580
Mohs, R. C., Knopman, D. S., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L. A., Geldmacher, D., Clark, C., et al. (1997) · PubMed · Cited by 487
Nicotinic acetylcholine binding sites in Alzheimer's disease
Whitehouse, P. J., Martino, A. M., Antuono, P. G., Lowenstein, P. R., Coyle, J. T., Price, D. L., & Kellar, K. J. (1986) · Brain Research · doi:10.1016/0006-8993(86)90819-x · Cited by 486
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
Albuquerque, E. X., Alkondon, M., Pereira, E. F. R., Castro, N. G., Schrattenholz, A., Barbosa, C. T. F., Bonfante-Cabarcas, R., Aracava, Y., Eisenberg, H. M., & Maelicke, A. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36503-6 · Cited by 445
Nordberg, A., & Svensson, A.-L. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Ferris, S. H., Schmitt, F. A., Grundman, M., & Thomas, R. G. (1997) · Alzheimer Disease · doi:10.1007/978-1-4612-4116-4_64 · Cited by 303
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
Morris, J. C., Cyrus, P. A., Orazem, J., Mas, J., Bieber, F., Ruzicka, B. B., & Gulanski, B. (1998) · Neurology · doi:10.1212/wnl.50.5.1222 · Cited by 287
Newhouse, P. A., Potter, A., & Levin, E. D. (1997) · Drugs & Aging · doi:10.2165/00002512-199711030-00005 · Cited by 267
The cholinergic hypothesis of Alzheimer's disease: a review of progress
BABIC;, T., FRANCIS, P. T., PALMER, A. M., SNAPE, M., & WILCOCK, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.558 · Cited by 255
Bores, G. M., Huger, F. P., Petko, W., Mutlib, A. E., Camacho, F., Rush, D. K., Selk, D. E., Wolf, V, Kosley, R. W., Davis, L., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12928-5 · Cited by 248
Schrattenholz, A., Pereira, E. F., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08675-4 · Cited by 226
Survival in Alzheimer's disease and vascular dementias
Barclay, L. L., Zemcov, A., Blass, J. P., & Sansone, J. (1985) · Neurology · doi:10.1212/wnl.35.6.834 · Cited by 225
Changes in functional status and the risks of subsequent nursing home placement and death.
Wolinsky, F. D., Callahan, C. M., Fitzgerald, J. F., & Johnson, R. J. (1993) · PubMed · Cited by 200
Patterns of Caring for People with Dementia in Canada The Canadian Study of Health and Aging
Lindsay, J. (1994) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.1017/s0714980800006334 · Cited by 171
The Physiology and Pharmacology of Melatonin in Humans
Geoffriau, M., Brun, J., Chazot, G., & Claustrat, B. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023160 · Cited by 164
Raskind, M. A., Cyrus, P. A., Ruzicka, B. B., et al. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0510 · Cited by 99
Use of Goal Attainment Scaling to Measure Treatment Effects in an Anti-Dementia Drug Trial
Rockwood, K. J., Stolee, P., Howard, K. A., & Mallery, L. H. (1996) · Neuroepidemiology · doi:10.1159/000109923 · Cited by 85
Self-citationThal, L. J., Schwartz, G. E., Sano, M. C., Weiner, M., Knopman, D. S., Harrell, L. E., Bodenheimer, S. L., Rossor, M. N., Philpot, M. P., Schor, J., et al. (1996) · Neurology · doi:10.1212/wnl.47.6.1389 · Cited by 80
Pharmacologic treatment of cognition in Alzheimer's dementia
Farlow, M. R., & Evans, R. M. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s36 · Cited by 64
Antuono, P. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430160102010 · Cited by 63
Rockwood, K. J., & MacKnight, C. (2001) · Neuroepidemiology · doi:10.1159/000054761 · Cited by 62
Self-citationChapter 35 The role of nicotinic receptors in the pathophysiology ofAlzheimer's disease
Nordberg, A. K., Nilsson-Håkansson, L., Adem, A., Hardy, J., Alafuzoff, I. I., Lai, Z., Herrera‐Marschitz, M., & Winblad, B. G. (1989) · Progress in brain research · doi:10.1016/s0079-6123(08)62495-4 · Cited by 56
[Characteristics of galanthamine as a reversible inhibitor of cholinesterase].
Vasilenko, E. T., & Tonkopiĭ, V. D. (1974) · PubMed · Cited by 52
New therapeutic approaches to Alzheimer's disease.
Schneider, L. S. S. (1996) · PubMed · Cited by 44
Do We Have Drugs for Dementia?
Pryse-Phillips, W. E. M. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.735-a · Cited by 34
Predictors of the Placement of Cognitively Impaired Residents on Special Care Units
Rn, R., & Fries, B. E. (1992) · The Gerontologist · doi:10.1093/geront/32.2.184 · Cited by 31
A Case Control Study of the Risks for Institutionalization of Elderly People in Nova Scotia
Glazebrook, K., Rockwood, K. J., Stolee, P., Fisk, J. D., & Gray, J. M. (1994) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.1017/s0714980800006590 · Cited by 25
Self-citationGalantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
(2000) · Neurology · doi:10.1212/wnl.55.5.744 · Cited by 22
Effectiveness of rivastigmine in Alzheimer's disease
Bentham, P., Gray, R. G., Sellwood, E., Raftery, J., Rösler, M., Selai, C. E., Trimble, M., Rossor, M. N., Harvey, R. J., Storosum, J. G., et al. (1999) · BMJ · doi:10.1136/bmj.319.7210.640a · Cited by 21
Treatment of Alzheimer Disease
Hachinski, V. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.735 · Cited by 20
What Randomized Trials and Systematic Reviews Can Offer Decision Makers
Altman, D. G. (1999) · Hormone Research in Paediatrics · doi:10.1159/000053134 · Cited by 18
Cited by
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Heinrich, M., & Lee Teoh, H. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.012 · Cited by 584
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Metadata
- Authors
- Rockwood, K.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2001-11-01
- Volume
- 71
- Issue
- 5
- Pages
- 589-595
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2152370183
- Cited by
- 279
- References
- 58
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.